by TractManager | Apr 15, 2021 | Emerging Technology Report
Breyanzi (lisocabtagene maraleucel [liso-cel]) is an autologous chimeric antigen receptor (CAR) T-cell therapy, a novel type of immunotherapy in which a patient’s own immune cells are genetically re-programmed to target and attack cancer cells. It is indicated for the...
by TractManager | Apr 14, 2021 | Emerging Technology Report
Sutimlimab is an intravenous monoclonal antibody targeting complement component 1s (C1s) for the treatment of cold agglutinin disease.If you have a Hayes login, click here to view the full report on the Knowledge Center.
by TractManager | Apr 13, 2021 | Emerging Technology Report
Sotorasib (AMG 510) is an investigational oral KRAS G12C inhibitor designed to block the abnormal proliferative action of mutant KRAS protein. It is under investigation for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with KRAS...
by TractManager | Apr 13, 2021 | News
These safety communications were recently posted by the Food and Drug Administration (FDA):Medtronic ICD and CRT-D Recall The FDA has announced a Class I recall of Medtronic’s Evera and Visia implantable cardioverter defibrillators (ICDs) and Viva, Claria, Amplia, and...
by TractManager | Apr 13, 2021 | Molecular Test Assessment
This report evaluates the analytical validity, clinical validity, and clinical utility of the Prospera test. If you have a Hayes login, click here to view the full report on the Knowledge Center.
Recent Comments